Egrifta Purple Book BLA 022505

BLA number
022505
Proprietary names
Egrifta, Egrifta SV, Egrifta WR
Proper names
tesamorelin
Applicant
Theratechnologies Inc.
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Egriftatesamorelin351(a)1MGFor InjectionSubcutaneousSingle-Dose VialDiscLicensed2010-11-10
002Egrifta SVtesamorelin351(a)2MGFor InjectionSubcutaneousSingle-Dose VialRxLicensed2011-11-29
003Egrifta WRtesamorelin351(a)11.6MGFor InjectionSubcutaneousMulti-Dose VialRxLicensed2025-03-25

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2026-01-01N003Egrifta WR351(a)RxTheratechnologies Inc.
2024-03-01U001Egrifta351(a)DiscTheratechnologies Inc.
2024-03-01U002Egrifta SV351(a)RxTheratechnologies Inc.
2021-04-01U001Egrifta351(a)DiscTheratechnologies Inc.
2021-04-01U002Egrifta SV351(a)RxTheratechnologies Inc.
2020-08-01U001Egrifta351(a)DiscTheratechnologies Inc.
2020-05-01R001Egrifta351(a)RxTheratechnologies Inc.
2020-05-01R002Egrifta SV351(a)RxTheratechnologies Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2026-01-01003Egrifta WR351(a)RxLicensed2025-03-25
2024-03-01001Egrifta351(a)DiscLicensed2010-11-10
2024-03-01002Egrifta SV351(a)RxLicensed2011-11-29
2020-08-01001Egrifta351(a)DiscLicensed2010-11-10
2020-05-01001Egrifta351(a)RxLicensed2010-11-10
2020-05-01002Egrifta SV351(a)RxLicensed2011-11-29